Top-Rated StocksTop-RatedNASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free IDYA Stock Alerts $38.62 -1.23 (-3.09%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$37.81▼$39.9350-Day Range$37.13▼$47.1352-Week Range$18.09▼$47.74Volume734,655 shsAverage Volume563,509 shsMarket Capitalization$2.89 billionP/E RatioN/ADividend YieldN/APrice Target$46.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get IDEAYA Biosciences alerts: Email Address IDEAYA Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside20.7% Upside$46.60 Price TargetShort InterestBearish14.86% of Float Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.00Based on 3 Articles This WeekInsider TradingSelling Shares$1.16 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.26) to ($2.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.12 out of 5 starsMedical Sector307th out of 908 stocksPharmaceutical Preparations Industry138th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingIDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIDEAYA Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.86% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.Change versus previous monthShort interest in IDEAYA Biosciences has recently increased by 4.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEAYA Biosciences has received a 72.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEAYA Biosciences is -0.79. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for IDEAYA Biosciences this week, compared to 3 articles on an average week.Search Interest3 people have searched for IDYA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,164,826.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($2.26) to ($2.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -19.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -19.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About IDEAYA Biosciences Stock (NASDAQ:IDYA)IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Read More IDYA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDYA Stock News HeadlinesApril 26, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | prnewswire.comIDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored StudyApril 26, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 22, 2024 | prnewswire.comIDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung CancerApril 18, 2024 | americanbankingnews.comShort Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Increases By 6.7%April 5, 2024 | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations EventMarch 20, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - IDYAApril 26, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 13, 2024 | markets.businessinsider.comStrong Buy Rating for IDEAYA Biosciences Based on Strategic Partnership and Promising Oncology PipelineMarch 12, 2024 | seekingalpha.comIdeaya inks clinical trial pact with MerckMarch 12, 2024 | msn.comIdeaya gains after clinical trial pact with MerckMarch 12, 2024 | markets.businessinsider.comIDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial CancerMarch 12, 2024 | prnewswire.comIDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerMarch 10, 2024 | benzinga.comIDEAYA Biosciences Stock (NASDAQ:IDYA), Quotes and News SummaryMarch 8, 2024 | markets.businessinsider.comDemystifying IDEAYA Biosciences: Insights From 6 Analyst ReviewsMarch 4, 2024 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations EventsFebruary 26, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD)February 24, 2024 | msn.comIDEAYA Biosciences (IDYA) Price Target Increased by 28.90% to 51.57February 23, 2024 | finance.yahoo.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent ResultsFebruary 21, 2024 | markets.businessinsider.comThe Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 ExpertsFebruary 20, 2024 | realmoney.thestreet.comIdeaya Biosciences price target raised by $10 at Oppenheimer, here's whyFebruary 20, 2024 | benzinga.comRecap: IDEAYA Biosciences Q4 EarningsFebruary 20, 2024 | markets.businessinsider.comIDEAYA Biosciences Q4 Results Misses EstimatesFebruary 20, 2024 | finance.yahoo.comIDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateFebruary 20, 2024 | prnewswire.comIDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateFebruary 16, 2024 | seekingalpha.comIdeaya Biosciences: A Strong Bet In Targeted OncologySee More Headlines Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/26/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IDYA CUSIPN/A CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees124Year FoundedN/APrice Target and Rating Average Stock Price Target$46.60 High Stock Price Target$60.00 Low Stock Price Target$33.00 Potential Upside/Downside+20.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net Margins-483.05% Pretax Margin-483.05% Return on Equity-23.00% Return on Assets-21.78% Debt Debt-to-Equity RatioN/A Current Ratio19.65 Quick Ratio19.65 Sales & Book Value Annual Sales$23.39 million Price / Sales123.47 Cash FlowN/A Price / Cash FlowN/A Book Value$9.64 per share Price / Book4.01Miscellaneous Outstanding Shares74,765,000Free Float70,952,000Market Cap$2.89 billion OptionableOptionable Beta0.80 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Yujiro S. Hata (Age 50)President, CEO & Director Comp: $851.7kDr. Michael A. White Ph.D. (Age 58)Chief Scientific Officer Comp: $613.85kDr. Darrin M. Beaupre M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $152.64kMr. Andres Ruiz Briseno CPA (Age 37)Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations Dr. Paul A. Barsanti Ph.D.Chief Technology OfficerMr. Jason S. Throne Esq. (Age 52)J.D., Chief Legal Officer & Company Secretary Comp: $425.56kMr. Mick O'QuigleyChief of Staff & Clinical DevelopmentMore ExecutivesKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRMoonLake ImmunotherapeuticsNASDAQ:MLTXACADIA PharmaceuticalsNASDAQ:ACADCrinetics PharmaceuticalsNASDAQ:CRNXXenon PharmaceuticalsNASDAQ:XENEView All CompetitorsInsiders & InstitutionsJTC Employer Solutions Trustee LtdBought 1,547 shares on 4/19/2024Ownership: 0.002%Vanguard Group Inc.Bought 504,275 shares on 3/11/2024Ownership: 4.662%Fisher Asset Management LLCBought 508,151 shares on 3/5/2024Ownership: 0.724%Wellington Management Group LLPBought 83,984 shares on 3/5/2024Ownership: 0.113%Virtu Financial LLCBought 16,369 shares on 2/26/2024Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions IDYA Stock Analysis - Frequently Asked Questions Should I buy or sell IDEAYA Biosciences stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDYA shares. View IDYA analyst ratings or view top-rated stocks. What is IDEAYA Biosciences' stock price target for 2024? 12 Wall Street analysts have issued 12-month price targets for IDEAYA Biosciences' shares. Their IDYA share price targets range from $33.00 to $60.00. On average, they anticipate the company's share price to reach $46.60 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price. View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts. How have IDYA shares performed in 2024? IDEAYA Biosciences' stock was trading at $35.58 at the beginning of 2024. Since then, IDYA stock has increased by 8.5% and is now trading at $38.62. View the best growth stocks for 2024 here. Are investors shorting IDEAYA Biosciences? IDEAYA Biosciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 6.7% from the March 15th total of 8,820,000 shares. Based on an average daily volume of 905,000 shares, the days-to-cover ratio is currently 10.4 days. Approximately 14.3% of the company's shares are sold short. View IDEAYA Biosciences' Short Interest. When is IDEAYA Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our IDYA earnings forecast. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.05. The business earned $3.90 million during the quarter, compared to analysts' expectations of $8.84 million. IDEAYA Biosciences had a negative trailing twelve-month return on equity of 23.00% and a negative net margin of 483.05%. The company's revenue for the quarter was down 3.0% on a year-over-year basis. What ETFs hold IDEAYA Biosciences' stock? ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), Jacob Forward ETF (JFWD), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA). When did IDEAYA Biosciences IPO? IDEAYA Biosciences (IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO. Who are IDEAYA Biosciences' major shareholders? IDEAYA Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include JTC Employer Solutions Trustee Ltd (0.00%). Insiders that own company stock include Briseno Andres Ruiz, Jason Throne, Michael P Dillon, Michael P Dillon, Paul A Stone and Yujiro S Hata. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IDYA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
